A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia

被引:129
作者
Grant, GJ
Barenholz, Y
Bolotin, EM
Bansinath, M
Turndoft, H
Piskoun, B
Davidson, EM
机构
[1] NYU, Med Ctr, Dept Anesthesiol, Sch Med, New York, NY 10016 USA
[2] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Anesthesiol & Crit Care, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, Lab Membrane & Lipsome Res, Jerusalem, Israel
关键词
D O I
10.1097/00000542-200407000-00021
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background. Currently available local anesthetics have relatively brief durations of action. An ultralong-acting local anesthetic would benefit patients with acute and chronic pain. The authors prepared and characterized a novel liposomal bupivacaine formulation using remote loading of bupivacaine along an ammonium sulfate gradient and assessed its efficacy in humans. Methods: A large multivesicular liposomal bupivacaine formulation was prepared by subjecting small unilamellar vesicles to successive freeze-and-thaw cycles. Bupivacaine hydrochloride was then remotely loaded into the liposomes along an ammonium sulfate gradient ([(NH4)(2)SO4)](intraliposome)/ [(NH4)(2)SO4)](medium) > 1,000). The liposomes were then characterized for size distribution; drug-to-phospholipid ratio; in vitro release profile at 4degrees, 21degrees, and 37degreesC; sterility; and pyrogenicity. Six subjects each received six intradermal injections in the lower back with 0.5 ml of 0.5, 1.0, and 2% liposomal bupivacaine; 0.5% standard bupivacaine; saline; and "empty" liposomes. Duration of analgesia was assessed using pinprick testing of the skin directly over the injection sites. Results were compared using the log-rank test. Results: The mean large multivesicular vesicle size was 2,439 +/- 544 nm, with a drug-to-phospholipid ratio of 1.8, fivefold greater than results previously reported. In vitro release was slowest at 4degreesC. The median duration of analgesia with 0.5% standard bupivacaine was 1 h. The median durations of analgesia after 0.5, 1.0, and 2.0% liposomal bupivacaine were 19, 38, and 48 h, respectively. Neither saline nor "empty" liposomes produced analgesia. Conclusions: This novel liposomal formulation had a favorable drug-to-phospholipid ratio and prolonged the duration of bupivacaine analgesia in a dose-dependent manner. If these results in healthy volunteers can be duplicated in the clinical setting, this formulation has the potential to significantly impact the management of pain.
引用
收藏
页码:133 / 137
页数:5
相关论文
共 23 条
[1]   Liposome application: problems and prospects [J].
Barenholz, Y .
CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 2001, 6 (01) :66-77
[2]  
Barenholz Y., 1993, LIPOSOME TECHNOLOGY, P527
[3]  
Boogaerts J, 1995, Acta Anaesthesiol Belg, V46, P19
[4]   EPIDURAL ADMINISTRATION OF LIPOSOME-ASSOCIATED BUPIVACAINE FOR THE MANAGEMENT OF POSTSURGICAL PAIN - A FIRST-STUDY [J].
BOOGAERTS, JG ;
LAFONT, ND ;
DECLERCQ, AG ;
LUO, HC ;
GRAVET, ET ;
BIANCHI, JA ;
LEGROS, FJ .
JOURNAL OF CLINICAL ANESTHESIA, 1994, 6 (04) :315-320
[5]   Acute pain [J].
Carr, DB ;
Goudas, LC .
LANCET, 1999, 353 (9169) :2051-2058
[6]   A quantitative model for using acridine orange as a transmembrane pH gradient probe [J].
Clerc, S ;
Barenholz, Y .
ANALYTICAL BIOCHEMISTRY, 1998, 259 (01) :104-111
[7]   TOPICAL ANESTHESIA OF THE SKIN BY LIPOSOME-ENCAPSULATED TETRACAINE [J].
GESZTES, A ;
MEZEI, M .
ANESTHESIA AND ANALGESIA, 1988, 67 (11) :1079-1081
[8]  
GRANT GJ, 1994, REGION ANESTH, V19, P264
[9]   An in vivo method for the quantitative evaluation of local anesthetics [J].
Grant, GJ ;
Piskoun, B ;
Lin, A ;
Bansinath, M .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 43 (01) :69-72
[10]   Analgesic duration and kinetics of liposomal bupivacaine after subcutaneous injection in mice [J].
Grant, GJ ;
Piskoun, B ;
Bansinath, M .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2003, 30 (12) :966-968